SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing intense community speculation as investors debate potential short squeezes and price volatility, fueled by its low circulating supply and high-beta nature within the Solana ecosystem. Supporters are actively calling for accumulation while monitoring critical support levels and volume shifts, viewing the token as a high-upside play compared to larger market counterparts.

WorldFinancial

World Liberty Financial (WLFI) is facing intense community debate as investors speculate on a major token lockup and burn proposal intended to address supply concerns. While some traders view the current price volatility as a potential setup for a short squeeze, many critics are actively highlighting concerns over transparency, the project's governance, and ongoing legal challenges tied to the Trump family brand.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS Tech Inc. is trending as traders speculate on a potential short squeeze fueled by its micro-float structure and recent price volatility. The community remains divided, with bulls pointing to historical patterns of rapid appreciation in low-float stocks, while bears warn of the risks associated with potential dilution and the company's financial history.

Pershing Square, Inc. operates as an alternative asset management company. It operates through the following business segments: Operating Assets, MPC,and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multifamily properties along with other real estate investments. The MPC segments offers the development and sale of land in large-scale, long-term community development projects. The Strategic Developments segment provides residential condominium and commercial property projects currently under development. The company was founded by William A. Ackman on December 17, 2003 and is headquartered in New York, NY.

Pershing Square Inc.

Pershing Square Inc

Pershing Square is attracting significant attention as investors react to Bill Ackman's recent dual IPO launch and ongoing dialogues regarding the fund's management strategy. Community members are actively debating the firm's long-term potential as a next-generation investment vehicle while tracking its price volatility following the high-profile public debut.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Crypto is trending as its community aggressively rallies behind the project's roots in internet meme history and its restored web tools. Investors are showcasing strong conviction in the token, frequently sharing bullish sentiment and highlighting active community-led efforts to boost its market visibility.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is currently trending following a positive regulatory ruling from NOAA that its deep-sea mining application is in full compliance, a milestone that has renewed community focus on the firm's path toward commercial recovery. Investors remain highly vocal, debating the timing of potential Allseas partnerships and analyzing the long-term strategic role of deep-sea minerals in securing domestic supply chains.

Pump.fun

Pump.fun is generating significant community conversation as traders weigh its rapid memecoin deployment against concerns over volatility and sustainability. While some participants are actively participating in buyback campaigns and promoting new projects on the platform, others remain skeptical due to the high volume of rapid token turnover and common market risks.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DRB is gaining significant momentum on the Base chain as the community rallies around the narrative that Grok AI has accumulated substantial wealth through the token. Investors are actively discussing the potential for a major breakout, driven by the project's unique AI-to-AI origin and persistent speculation regarding future listing support and platform integration.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed is drawing significant investor attention after confirming the receipt of nearly $700 million in federal tax refunds, a cash injection that analysts note exceeds the company's current market capitalization. Community discourse is heavily focused on the stock's potential for a massive short squeeze, with many users highlighting the high short interest and improved balance sheet liquidity as catalysts for a potential rally.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Cronos ($CRO) is facing intense community skepticism regarding its ongoing token dilution and exchange leadership, even as supporters point to potential catalysts like upcoming Cronos app updates and ETF filings. Meanwhile, the community is actively debating the project's long-term viability against meme coin alternatives and broader market movements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The open-label study evaluated Celcuity’s investigational gedatolisib in combination with fulvestrant, both with and without palbociclib.</li><li>Celcuity plans to submit the results to the FDA as part of a supplemental New Drug Application and to other regulators thereafter.</li><li>Celcuity has submitted an application already for gedatolisib in patients with some types of breast cancer, on which the agency will decide on July 17.&nbsp;</li></ul>Shares of Celcuity Inc. (CELC) jumped 14% after hours after the company said on Friday that its experimental cancer drug delivered a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with certain advanced breast cancers.The open-label study evaluated Celcuity’s investigational gedatolisib in combination with fulvestrant, both with and without palbociclib. Patients had progressed after prior treatment with a palbociclib plus an aromatase inhibitor.Both the gedatolisib triplet and doublet regimens outperformed the control arm, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival.Both gedatolisib regimens were generally well tolerated with manageable safety profiles, the company said. Detailed data will be presented on June 2 at the ASCO Annual Meeting in Chicago.“These positive topline results demonstrate the potential for gedatolisib to become a transformative new medicine for the treatment of patients with PIK3CA-mutant HR+/HER2- advanced breast cancer,” said Igor Gorbatchevsky, Celcuity’s chief medical officer.Celcuity plans to submit the results to the FDA as part of a supplemental New Drug Application and to other regulators thereafter.Celcuity has submitted an application already for gedatolisib in patients with some types of breast cancer, on which the agency will decide on July 17. The agency also granted priority review to the drug in the indication.<h2 class="st-heading-2">How Did CELC Retail Traders React?</h2>On Stocktwits, retail sentiment stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user applauded the trial data.<stembedurl>https://www.stocktwits.com/CharlieeMungerTWITS/message/652069628</stembedurl><a href="https://stocktwits.com/symbol/CELC">CELC stock</a> has rallied over 1000% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vnda-stock-rises-after-hours-on-commercial-launch-of-motion-sickness-drug/cZQVZvNReet">VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celcuity logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data

The company said that its experimental cancer drug delivered a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with certain advanced breast cancers.

Equity

The company said that its experimental cancer drug delivered a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with certain advanced breast cancers.


<ul class="summary-bullets"><li>The drug offers simple dosing with just one or two capsules a day taken approximately an hour before travel.</li><li>Patients can access Nereus at a cash-pay price of just $85 per dose, a meaningful discount from the standard list price of $255 per dose, the company said.</li><li>Vanda is also studying the drug in gatroparesis and the prevention of nausea and vomiting induced by GLP-1 drugs popularly used for weight loss and diabetes.</li></ul> Shares of Vanda Pharmaceuticals Inc. (VNDA) jumped 4% after hours on Friday after the company announced that its motion sickness drug is now commercially available across the U.S.The U.S. Food and Drug Administration approved Nereus for the prevention of vomiting induced by motion in adults in December. The FDA approval marked the first new pharmacologic treatment for motion sickness in more than 40 years.<h2 class="st-heading-2">Clinical Data For Nereus</h2>According to Vanda, motion sickness affects roughly 25 to 30% of adults during everyday travel by car, plane, or boat. Patients can now access the drug from the company’s dedicated direct-to-consumer portal for the drug or from retail pharmacies with a prescription. Patients can access Nereus at a cash-pay price of just $85 per dose, a meaningful discount from the standard list price of $255 per dose, the company said.The FDA approved Nereus following two late-stage trials conducted under real-world conditions on the open sea. In both trials, Nereus significantly prevented vomiting compared to placebo, confirming the drug's effectiveness. The drug offers simple dosing with just one or two capsules a day taken approximately an hour before travel.Vandas is also studying the drug in gatroparesis and the prevention of nausea and vomiting induced by GLP-1 drugs popularly used for weight loss and diabetes.<h2 class="st-heading-2">How Did VNDA Retail Traders React?</h2>On Stocktwits, retail sentiment around VNDA stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours while message volume remained at ‘normal’ levels.A Stocktwits user opined that the company could be bought out by GLP-1 drug makers like Eli Lilly, Novo Nordisk, or Pfizer in light of its efforts in treating the side effects of those drugs.<stembedurl>https://www.stocktwits.com/hktrader12/message/652070630</stembedurl><a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> has gained 58% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nspr-rallies-after-hours-on-fda-green-light-for-key-stroke-prevention-trial/cZQVklHReeA">NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game between the Chicago White Sox and the Detroit Tigers on September 05, 2025. (Photo by Joseph Weiser/Icon Sportswire via Getty Images)

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug

The U.S. Food and Drug Administration approved Nereus for the prevention of vomiting induced by motion in adults in December.

<ul class="summary-bullets"><li>Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier.</li><li>Piper Sandler lowered its price target on Summit to $16 from $17 and maintained a ‘Neutral’ rating on the shares.</li><li>The company’s interim update from its HARMONi-3 trial disappointed investors.&nbsp; Final data from the cohort remain on track for the second half of 2026.</li></ul> Shares of Summit Therapeutics Inc. (SMMT) closed 25% lower on Friday after the company reported a wider loss for the first quarter and an interim analysis update from its HARMONi-3 trial, prompting Piper Sandler to lower its price target on the stock.Piper Sandler lowered its price target on Summit to $16 from $17 and maintained a ‘Neutral’ rating on the shares.<h2 class="st-heading-2">Summit’s Q1 Earnings</h2>Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier, as the company ramps up spending on its lead asset ivonescimab in the treatment of non-small cell lung cancer (NSCLC).The company is studying Ivonescimab combined with chemotherapy in patients with first-line metastatic NSCLC in its HARMONi-3 trial, with two distinct cohorts to be analyzed separately for squamous tumors and non-squamous tumors.In squamous tumors, an independent Data Monitoring Committee completed a pre-specified interim progression-free survival analysis in Q2 2026 and recommended that the study continue as planned with no safety concerns, the company said. However, it did not hit the high statistical bar for early success/stop. Final data from the cohort remain on track for the second half of 2026.In the non-squamous tumors cohort, enrollment is expected to be completed by the end of Q2 2026, and data readout is targeted for the first half of 2027.According to Piper Sandler, investors are now questioning whether the impressive effect size seen in Akeso's HARMONi-6 can be replicated in Summit's global HARMONi-3.HARMONi-6 is a trial conducted in China and sponsored by Akeso, which evaluates ivonescimab in combination with platinum-based chemotherapy compared with the drug tislelizumab and platinum-based chemotherapy in non-small cell lung cancer.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SMMT stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user dismissed the selloff as an overreaction.<stembedurl>https://www.stocktwits.com/northern18738901/message/652058452</stembedurl>Another echoed the sentiment, expressing optimism for the stock to rally back up over $18 in two weeks.<stembedurl>https://www.stocktwits.com/BobBijawklah/message/652053579</stembedurl><a href="https://stocktwits.com/symbol/SMMT">SMMT stock</a> has fallen 35% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nspr-rallies-after-hours-on-fda-green-light-for-key-stroke-prevention-trial/cZQVklHReeA">NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update

Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier.

<ul class="summary-bullets"><li>While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs, it said.&nbsp;</li><li>However, the experimental therapy demonstrated a differentiated tolerability profile with fewer gastrointestinal, dermatologic, and subcutaneous adverse events as compared to other drugs belonging to its category.&nbsp;</li><li>The company also clarified that the decision to discontinue JANX008 is program-specific and part of its efforts to prioritize parts of its portfolio.</li></ul>Shares of Janux Therapeutics, Inc. (JANX) edged up 1% after hours after the company said on Monday that it will discontinue development of its experimental program called JANX008 to focus its resources on its remaining pipeline.The company said that it came to the decision after completing early-stage trials across multiple solid tumor indications and an internal review of the data. While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs, it said.However, the experimental therapy demonstrated a differentiated tolerability profile with fewer gastrointestinal, dermatologic, and subcutaneous adverse events as compared to other drugs belonging to its category, the company said. Overall safety profile also allows for outpatient dosing, the company noted.The company also clarified that the decision to discontinue JANX008 is program-specific and part of its efforts to prioritize parts of its portfolio.“Our decision to discontinue JANX008 reflects the disciplined approach we take to advancing our pipeline,” said David Campbell, Ph.D., President and Chief Executive Officer of Janux. “We evaluate each program against a high bar for safety, activity, and differentiated profile. We prioritize resources toward programs that meet these criteria and offer opportunities to deliver best-in-class outcomes.”Janux is currently also evaluating other experimental drugs for the treatment of prostate cancer as well as autoimmune diseases. Earlier this month, the company said that it dosed the first participant in an early-stage study of JANX014, one of its candidates for prostate cancer.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around JANX fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.JANX stock has fallen 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/crmd-stock-jumps-as-antifungal-drug-clears-key-trial-for-2-billion-preventive-market/cZBNx6bRePY">CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Janux Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline

The company said that it came to the decision after completing early-stage trials across multiple solid tumor indications and an internal review of the data.

<ul class="summary-bullets"><li>BTIG added that updated Phase 1 PK/PD data also suggest ORKA-001 could enable once-yearly maintenance dosing, which the firm believes would be a first for any monoclonal antibody.</li><li>The firm raised its price target for Oruka by 94%, to $151 from $78, and maintained a ‘Buy’ rating on the stock.</li><li>Analysts at Guggenheim also hiked their price target for Oruka to $200 from $125, while adding that the company now has the potential to reach a peak of $7 billion in global sales for the psoriasis therapy.</li></ul>Shares of Oruka Therapeutics Inc. (ORKA) were on track for their best single-day gains in more than a month after the company announced interim results from a trial of its moderate-to-severe plaque psoriasis therapy.Oruka Therapeutics announced that 40 of the 63 participants in the EVERLAST-A Phase 2a trial of ORKA-001, a novel, half-life-extended IL-23p19 monoclonal antibody, met the primary endpoint.<a href="https://stocktwits.com/symbol/ORKA">Oruka Therapeutics shares</a> were up more than 20% in Monday’s opening trade.<h2 class="st-heading-2">BTIG Turns Bullish On Oruka</h2>According to TheFly, analysts at BTIG turned bullish on Oruka Therapeutics following the company’s interim trial results. The firm raised its price target for Oruka by 94%, to $151 from $78, and maintained a ‘Buy’ rating on the stock.BTIG added that updated Phase 1 PK/PD data also suggest ORKA-001 could enable once-yearly maintenance dosing, which the firm believes would be a first for any monoclonal antibody.BTIG stated that ORKA-001 has strong potential to become the preferred IL-23 inhibitor if approved, citing best-in-class efficacy and roughly one-fourth the maintenance injection burden of AbbVie’s (ABBV) Skyrizi.Analysts at Guggenheim also hiked their price target for Oruka to $200 from $125, while keeping a ‘Buy’ rating on the stock. The firm believes ORKA-001 has multi-billion-dollar blockbuster potential, adding that Oruka now has the potential to reach a peak of $7 billion in global sales for the psoriasis therapy.<h2 class="st-heading-2">Oruka’s Findings In The Trial</h2>Oruka stated that 64% of the participants in the trial achieved complete skin clearance in the 16th week.The company stated that key secondary endpoints were also strong, with 83% reaching PASI 90 during this period.In the placebo group, one of 21 participants met these endpoints, which it said was consistent with historical psoriasis trials.Oruka stated that cross-trial comparisons suggest ORKA-001 delivers higher skin clearance rates than other IL-23p19 inhibitors and ranks among the best reported in plaque psoriasis across all treatment types.The company stated that it plans to release longer-term EVERLAST-A data in the second half of 2026, including Week 28 results for all patients, along with a 52-week follow-up for a subset. Oruka also added that it will continue to advance the Phase 2b EVERLAST-B trial, with data expected in 2027.PASI refers to the Psoriasis Area and Severity Index. It quantifies the severity and extent of psoriasis symptoms across body regions. PASI 90 refers to a 90% or more improvement. Similarly, PASI 100 denotes a 100% improvement over baseline.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ORKA">Oruka Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels as of this writing.One bullish user believes ORKA stock could reach $200 per share soon.<stembedurl>https://stocktwits.com/Chiefstaff/message/651484000</stembedurl><a href="https://stocktwits.com/symbol/ORKA">ORKA stock</a> is up 172% year-to-date and 716% over the past 12 months. The S&amp;P Biotech ETF (XBI) is up 68% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 42%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/microsoft-loses-exclusive-license-openai-models-taps-anthropic-claude/cZBNAqiRePg">Microsoft Loses Exclusive Access To OpenAI Models In Partnership Reset Ahead Of Q3 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

“We are pleased to have settled our lawsuit with the United States Department of Justice,” the LYV said in a statement as its stock closed higher. 

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

Oruka Therapeutics stated that 64% of the participants in the Phase 2a EVERLAST-A trial of ORKA-001 met the study’s primary endpoint.

<ul class="summary-bullets"><li>The company stated that 62% of the patients in the trial who received lonvo-z were entirely free of HAE attacks during the six-month evaluation period, compared to 11% of patients who received placebo.</li><li>Lonvo-z is a one-time treatment administered in an outpatient setting.</li><li>Intellia Therapeutics also stated that it has initiated a rolling Biologics License Application submission to the U.S. Food and Drug Administration.</li></ul>Shares of Intellia Therapeutics Inc. (NTLA) soared in Monday’s pre-market trade after the company reported positive Phase 3 trial results in its therapy for a rare genetic condition.<a href="https://stocktwits.com/symbol/NTLA">Intellia Therapeutics shares</a> were up more than 9% before the bell on Monday, on track for the biggest gains in this month so far. NTLA was the top trending ticker on the platform at the time of writing.<h2 class="st-heading-2">Rare Genetic Condition Trial Meets All Endpoints</h2>Intellia Therapeutics stated that its Phase 3 trial of lonvoculin ziclumeran (lonvo-z) met the primary and secondary endpoints, with favorable safety and tolerability.The Cambridge, Massachusetts-based biopharmaceutical company evaluated lonvo-z for the treatment of hereditary angioedema (HAE), a rare genetic condition characterized by recurrent, sometimes life-threatening episodes of swelling (angioedema) in different parts of the body. This includes the face, upper airway, abdomen, and extremities due to bradykinin overproduction.The company designed lonvo-z as a one-time treatment that is administered in an outpatient setting. Lonvo-Z is an in vivo CRISPR gene-editing candidate designed to disable the kallikrein B1 (KLKB1) gene, aiming to permanently reduce kallikrein and bradykinin levels.“For those patients who have spent years battling unpredictable breakthrough swelling attacks, anxiety about their next attack or the many burdens associated with chronic prophylactic treatment, lonvo-z represents a potential paradigm shift in treatment,” said Intellia Therapeutics CEO John Leonard.The company stated that 62% of the patients in the trial who received lonvo-z were entirely free of HAE attacks during the six-month evaluation period, compared to 11% of patients who received a placebo.<h2 class="st-heading-2">Intellia Submits Application For FDA Approval</h2>Intellia Therapeutics also stated that it has initiated a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for approval.It is also preparing for a potential U.S. launch of lonvo-z in the first half of 2027.Intellia Therapeutics stated that it will present additional data at the 2026 European Academy of Allergy and Clinical Immunology Congress in June this year.The company said that one in 50,000 people is estimated to be affected by HAE.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NTLA">Intellia Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One user stated that gene editing is the future.<stembedurl>https://stocktwits.com/2h2guard/message/651485761</stembedurl>Another bullish user recommended investing now before it is too late for the perfect buying opportunity.<stembedurl>https://stocktwits.com/JuniorStocka/message/651485649</stembedurl><a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> is up 52% year-to-date and 67% over the past 12 months. The ARK Innovation ETF (ARKK) is up 53% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 65%.The iShares Russell 2000 ETF (IWM) is up 43% during this period, while the Vanguard Small-Cap Growth Index Fund ETF Shares (VBK) is up 36%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/qcom-stock-highest-level-3-months-wall-street-not-bullish-q2-earnings/cZBNZwBRe2M">QCOM Stock On Track To Open At Highest Levels In 3 Months, But Wall Street Is Cautious Ahead Of Q2 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late

Intellia Therapeutics stated that its Phase 3 trial of lonvoguran ziclumeran met the primary and secondary endpoints, with favorable safety and tolerability.

<ul class="summary-bullets"><li>If data from a third-stage trial is supportive, the company expects to submit an application to the U.S. Food and Drug Administration (FDA) seeking approval for the therapy in the second half of 2026.&nbsp;</li><li>The company will announce the data on Monday.&nbsp;</li><li>In addition to lonvoguran ziclumeran, Intellia is also developing another therapy called Nexiguran Ziclumeran (Nex-z) for Transthyretin (ATTR) Amyloidosis.</li></ul>Shares of Intellia Therapeutics (NTLA) jumped 22% after hours on Friday after the company said that it will announce clinical data from the late-stage trial of its experimental therapy lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday.Lonvo-z is designed to inactivate a gene in the liver, dramatically reducing or eliminating HAE attacks via a one-time treatment. Hereditary angioedema (HAE) is a rare, autosomal dominant genetic disorder causing recurrent, severe, non-itchy swelling in the limbs, face, intestinal tract, and airway.Intellia completed enrollment of 80 patients in the global study in September 2025, ahead of schedule. If data from the trial is supportive, the company expects to submit an application to the U.S. FDA seeking approval for the therapy in the second half of 2026, with a launch planned for the first half of 2027.In addition to lonvoguran ziclumeran, Intellia is also developing another therapy called Nexiguran Ziclumeran (Nex-z) for Transthyretin (ATTR) Amyloidosis. The U.S. Food and Drug Administration imposed a clinical hold on the company’s clinical trials in October after a patient experienced severe liver complications and subsequently died, but lifted the hold earlier this year, allowing the trials to proceed.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around NTLA stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels. &nbsp;A Stocktwits user highlighted that the data announcement is coming earlier than expected and wondered if the move signals confidence. In February, the company had pitched the data announcement for mid-2026.&nbsp; <stembedurl>https://www.stocktwits.com/Monkey7779192/message/651352863</stembedurl>Another user warned caution in light of the stock surge.<stembedurl>https://www.stocktwits.com/sister/message/651352429</stembedurl>A third user said that they have “a good feeling” about the upcoming readout.<stembedurl>https://www.stocktwits.com/Beyzade/message/651356875</stembedurl><a href="https://stocktwits.com/symbol/NTLA">NTLA stock </a>has gained 67% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ihrt-stock-soars-on-merger-talks-with-sirius-xm-report/cZBhkrJRecp">IHRT Stock Soars On Merger Talks With Sirius XM: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy 

Lonvo-z is designed to inactivate a gene in the liver, dramatically reducing or eliminating HAE attacks via a one-time treatment.

<ul class="summary-bullets"><li>FDA refused to approve Replimune’s melanoma drug RP1 for the second time earlier this month, citing insufficient data to provide “substantial evidence of effectiveness.”</li><li>Doctors also called for a change in leadership at the FDA over its decision not to approve Replimune’s RP1.&nbsp;</li><li>According to a report from Reuters, Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had little role in the FDA’s decision to reject RP1.</li></ul>Shares of Replimune (REPL) jumped 22% on Wednesday after doctors who treat melanoma expressed disappointment over the U.S. Food and Drug Administration’s rejection of the company’s experimental drug RP1.FDA refused to approve Replimune’s melanoma drug RP1 for the second time earlier this month, citing insufficient data to provide “substantial evidence of effectiveness” in the treatment of unresectable advanced cutaneous melanoma.Doctors, in an opinion piece <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/opinion/fda-rp1-replimune-melanoma-drug-rfk-jr-vinay-prasad-marty-makary-b8d666b2?mod&amp;#61;Searchresults&amp;pos&amp;#61;1&amp;page&amp;#61;1">published</a> in The Wall Street Journal, criticized the FDA’s decision, noting that the initial panel that reviewed RP1 had recommended approval, which was later overruled by the then-FDA biologics chief, Vinay Prasad.The second team that reviewed the drug also did not say that the drug was ineffective, instead saying that it is “unclear whether the drug was effective,” the doctors said. Melanoma doctors organized and sent a letter to the FDA imploring it to approve RP1, they noted, while adding that they weren't asked by the pharma industry to do it.“Denying patients a life-saving medicine for inexplicable reasons is the wrong kind of change. If Dr. Makary doesn’t understand that, the FDA needs a change in leadership,” the doctors said.<h2 class="st-heading-2">Kennedy Distances Self</h2>According to a report from <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/us-health-secretary-kennedy-distances-himself-fdas-replimune-cancer-drug-2026-04-22/">Reuters</a>, Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had little role in the FDA’s decision to reject R1.He, instead, said that the decision was in the hands of FDA Commissioner Marty Makary."This decision comes out of FDA, and we trust ​the process there,” Kennedy reportedly said.<h2 class="st-heading-2">Replimune’s Efforts With RP1 Approval</h2>In late July 2025, the FDA had issued a complete response letter regarding the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency said in the letter then that it is unable to approve the application in its present form, and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness. It further urged that the company conduct and provide the results from a fresh trial for further consideration.Replimune subsequently resubmitted its application in October with additional information and analyses, but no additional trial.Earlier this month, the FDA said that the revised application does not alter its initial conclusion of the ineffectiveness of the trials conducted by the company. The agency also noted that the members of the team who reviewed the resubmission were different from those who reviewed the initial application to maintain objectivity.Replimune can either resubmit or withdraw its application within a year.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REPL stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘extremely low’ levels.A Stocktwits user opined that “REPL is done for the next two years” and added that the company needs a lifeline from another company.<stembedurl>https://www.stocktwits.com/CanaryMarketIntel/message/651056221</stembedurl>Another user reiterated confidence in the FDA’s decision to reject the drug.<stembedurl>https://www.stocktwits.com/PensionPulse/message/651038201</stembedurl>Another user, however, said that they are looking for 30X gains on REPL stock.<stembedurl>https://www.stocktwits.com/Rookie_investor/message/651040943</stembedurl><a href="https://stocktwits.com/symbol/REPL">REPL stock</a> has fallen 74% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ual-goes-silent-on-airline-merger-speculation-following-aal-snub/cZBBCayReb7">UAL Goes Silent On Airline Merger Speculation Following AAL Snub</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Ignites On Doctor Fury Against FDA’s Melanoma Drug Snub — Health Sec Steps Back

Doctors, in an opinion piece published on The Wall Street Journal, criticised the FDA’s decision, noting that the initial panel that reviewed RP1 recommended approval. 

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

<ul class="summary-bullets"><li>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia cells from natural programmed cell death, making them more vulnerable.</li><li>Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.</li><li>Meanwhile, Sellas’s late-stage trial of its lead candidate GPS in Acute Myeloid Leukemia is advancing toward final analysis.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) closed up 6% and edged up 2% after-hours on Friday, garnering heavy retail interest as investors anticipated upcoming data updates on its pipeline at the American Association for Cancer Research.According to Stocktwits platform data, retail chatter increased 36% over the past day, rising from ‘low’ to ‘normal’ levels.Sellas is slated to present preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center. Sellas will make its presentation on April 21.<h2 class="st-heading-2">Pipeline Optimism</h2>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia (AML) cells from natural programmed cell death, making them more vulnerable. Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.“The ability to lower apoptotic threshold in AML cells by suppressing key survival pathways and enhancing potency with repeated exposure further supports the development of SLS009, including in combination regimens,” said Dragan Cicic, Chief Development Officer of SELLAS.Sellas’s lead candidate, GPS, meanwhile, is being evaluated for its potential as a monotherapy and in combination with other therapies to address a broad spectrum of blood malignancies and solid tumor indications.The company’s late-stage trial of GPS in Acute Myeloid Leukemia is advancing toward final analysis. The final analysis is slated for when the company records the 80th patient death in the trial. In December, the company announced that 72 events had been completed and it will announce when the 80th event occurs. With event-driven trials like Sellas’s, the delay highlights longer survival, indicating potential for the therapy.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SLS stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours.A Stocktwits user said that the stock has two near-term catalysts in terms of the upcoming conference and update on the GPS program in AML.<stembedurl>https://www.stocktwits.com/55X_ROI_Q1_2026/message/650652881</stembedurl>Yet another sounded optimistic for the company’s pipeline, highlighting the many designations granted to Sellas’s experimental therapies.<stembedurl>https://www.stocktwits.com/gata2016/message/650649884</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy

Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.

XBI
SPDR S&P Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XBI News

XBISPDR S&P Biotech ETF